Valuation: GlucoTrack, Inc.

Market Cap 322K 287K 265K 241K 451K 30.55M 458K 3.19M 1.26M 15.99M 1.21M 1.18M 50.46M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -3.62M -3.23M -2.98M -2.7M -5.06M -343M -5.14M -35.87M -14.19M -180M -13.56M -13.28M -567M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.33%
Yield 2024 *
-
Yield 2025 -
1 day-32.67%
1 week-51.53%
Current month-75.41%
1 month-81.84%
3 months-91.21%
6 months-96.30%
Current year-99.31%
1 week 0.37
Extreme 0.3729
0.74
1 month 0.37
Extreme 0.3729
3.25
Current year 0.37
Extreme 0.3729
63.6
1 year 0.37
Extreme 0.3729
112.5
3 years 0.37
Extreme 0.3729
89,100.09
5 years 0.37
Extreme 0.3729
436,500.44
10 years 0.37
Extreme 0.3729
7,020,007.02
Manager TitleAgeSince
Chief Executive Officer 55 13/07/2026
Director of Finance/CFO 66 27/01/2025
Chief Operating Officer - 31/01/2025
Director TitleAgeSince
Director/Board Member 56 24/08/2023
Chairman 64 12/02/2024
Director/Board Member 78 13/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
26/03/25 Free

Director

4,490 0.0431%
25/03/25 Free

Director

8,747 0.0840%
25/03/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-32.67%-51.53%-99.59%-100.00% 478K
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average -3.02%-2.51%+34.86%+96.62% 38.19B
Weighted average by Cap. +0.38%+0.55%+48.17%+122.11%

Financials

2024 2025
Net sales - -
Net income -22.6M -20.17M -18.62M -16.9M -31.64M -2.15B -32.13M -224M -88.72M -1.12B -84.79M -82.99M -3.54B -19.39M -17.31M -15.98M -14.5M -27.15M -1.84B -27.57M -192M -76.12M -963M -72.75M -71.2M -3.04B
Net Debt -5.35M -4.78M -4.41M -4M -7.49M -508M -7.61M -53.09M -21M -266M -20.07M -19.65M -839M -3.94M -3.51M -3.24M -2.94M -5.51M -374M -5.6M -39.07M -15.46M -196M -14.77M -14.46M -617M
Projected Income Statement - Annual - GlucoTrack, Inc.
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
23/10/26 US$0.4032 -32.67% 670,425
22/10/26 US$0.5989 -6.28% 145,137
21/10/26 US$0.6390 -1.86% 74,253
20/10/26 US$0.6511 -4.91% 50,925
19/10/26 US$0.6847 -5.56% 102,789
  1. Stock Market
  2. Stocks
  3. GCTK Stock